Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug

At the heart of a $5 billion deal between Gilead Sciences and the Belgian biotech Galapagos is an experimental drug that regulates the immune system.

Clinical research has found the drug, known as filgotinib, to be an effective treatment for rheumatoid arthritis, enough so that Gilead in December asked the Food and Drug Administration to approve it.